Synthetic Biologics (SYN)

Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Company profile

Ticker

SYN

Exchange

NYSE

Website

www.syntheticbiologics.com

CEO

Steven Shallcross

Incorporated

Nevada

Location

Maryland

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

Former names

ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD MEDICAL TECHNOLOGIES INC, SHEFFIELD PHARMACEUTICALS INC

SEC CIK

0000894158

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Pipex Therapeutics, Inc. • Effective Pharmaceuticals, Inc. • Solovax, Inc. • CD4 Biosciences, Inc. • Epitope Pharmaceuticals, Inc. • Healthmine, Inc. • Putney Drug Corp. • Synthetic Biomics, Inc. • VCN Biosciences, S.L. ...

IRS number

133808303

SYN stock data

1M 1Y 5Y

News

From Benzinga Pro

Earnings Scheduled For August 11, 2022

11 Aug 22

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday

5 Aug 22

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share in cash.

Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session

4 Aug 22

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.

Why Is Yellow Trading Higher By 33%: Here Are 48 Stocks Moving Premarket

4 Aug 22

Synthetic Biologics Receives Notice Of Allowance For U.S. Patent Titled 'MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS'

27 Jul 22

Press releases

From Benzinga Pro

Synthetic Biologics to Participate in the BTIG Biotechnology Conference 2022

4 Aug 22

ROCKVILLE, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today

Synthetic Biologics Announces $3 Million Private Placement of Convertible Preferred Stock

29 Jul 22

ROCKVILLE, Md., July 29, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc.. (NYSE:SYN) ("Synthetic Biologics" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat diseases

Thinking about buying stock in Synthetic Biologics, Revelation Biosciences, Geovax Labs, Chimerix, or Zymergen?

25 Jul 22

NEW YORK, July 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SYN, REVB, GOVX, CMRX, and ZY.

Synthetic Biologics Announces Reverse Stock Split

15 Jul 22

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

11 Aug 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart SYN financial data

Quarter (USD)	Jun 22	Mar 22	Dec 21	Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	52.36M	52.36M	52.36M	52.36M	52.36M	52.36M
Cash burn (monthly)	1.48M	1.83M	1.66M	1.48M	1.45M	1.35M
Cash used (since last report)	2.15M	2.66M	2.42M	2.16M	2.11M	1.97M
Cash remaining	50.21M	49.7M	49.94M	50.21M	50.25M	50.39M
Runway (months of cash)	34.0	27.2	30.1	33.9	34.6	37.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

SYN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
23 Dec 21	Kraws Jeffrey J	Stock Options Common Stock	Grant	Acquire A	No	No	0.3314	200,000	66.28K	200,000
23 Dec 21	John J Monahan	Stock Options Common Stock	Grant	Acquire A	No	No	0.3314	200,000	66.28K	200,000
23 Dec 21	Steven A Shallcross	Stock Options Common Stock	Grant	Acquire A	No	No	0.3314	650,000	215.41K	650,000
23 Dec 21	Wolf Jeffrey Alan	Stock Options Common Stock	Grant	Acquire A	No	No	0.3314	200,000	66.28K	200,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

SYN institutional ownership history Ownership history

89.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	36	4	+800.0%
Opened positions	33	2	+1550.0%
Closed positions	1	36	-97.2%
Increased positions	1	0	NEW
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	5.42M	2.93M	+85.2%
Total shares	14.25M	5.76M	+147.3%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Vanguard	5.3M	$1.51M	NEW
Custodian Ventures	2.22M	$1.96M	0.0%
BLK Blackrock	1.89M	$538K	NEW
Geode Capital Management	1.13M	$321K	NEW
Iroquois Capital Management	908.2K	$247K	0.0%
STT State Street	486.92K	$139K	NEW
NTRS Northern Trust	336.4K	$96K	NEW
VIRT Virtu Financial	306.48K	$87K	NEW
Jane Street	281.7K	$80K	NEW
Blair William & Co	257.59K	$73K	NEW

Largest transactions	Shares	Bought/sold	Change
Vanguard	5.3M	+5.3M	NEW
Hudson Bay Capital Management	0	-2.61M	EXIT
BLK Blackrock	1.89M	+1.89M	NEW
Geode Capital Management	1.13M	+1.13M	NEW
STT State Street	486.92K	+486.92K	NEW
NTRS Northern Trust	336.4K	+336.4K	NEW
VIRT Virtu Financial	306.48K	+306.48K	NEW
Jane Street	281.7K	+281.7K	NEW
Blair William & Co	257.59K	+257.59K	NEW
Two Sigma Investments	163.17K	+163.17K	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Qualigen Therapeutics • Immune Therapeutics

Risks

We expect to seek to raise additional capital in the future, which may be dilutive to stockholders or impose operational restrictions.

Management Discussion

General and administrative expenses increased to $1.5 million for the three months ended June 30, 2022, from $1.3 million for the three months ended June 30, 2021. This increase of 19% primarily comprised of increased consulting and legal costs related to the VCN acquisition, higher insurance costs, audit fees, and public relations expenses and VCN administrative expenses not included in prior year. The charge related to stock-based compensation expense was $86,000 for the three months ended June 30, 2022, compared to $83,000 the three months ended June 30, 2021.
Research and development expenses increased to $3.5 million for the three months ended June 30, 2022, from approximately $1.9 million for the three months ended June 30, 2021. This increase of 80% is primarily the result of VCN research expenses related to VCN-01 not incurred in the prior year and to a lesser extent higher manufacturing expense for SYN-020, costs incurred related to our Phase 1a clinical trial of SYN-020 and expenses related to our Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients. We anticipate research and development expense to increase as we plan for and initiate enrollment for our phase 2 clinical trial for VCN-01 in PDAC, phase 2/3 clinical trial in retinoblastoma, expand GMP manufacturing activities for VCN-01, and continue with supporting our VCN-11 and other preclinical and discovery initiatives. The charge related to stock-based compensation expense was $27,000 for the three months ended June 30, 2022, compared to $19,000 related to stock-based compensation expense for the three months ended June 30, 2021.
Other income was $17,000 for the three months ended June 30, 2022 compared to other income of $2,000 for the three months ended June 30, 2021. Other income for the three months ended June 30, 2022 is primarily comprised of interest income of $26,000 offset by an exchange loss of $9,000. Other income for the three months ended June 30, 2021 is primarily comprised of interest income.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: alter, automatically, chimeric, doi, downturn, Enterobacteriaceae, evenly, fat, gain, German, lesser, Master, MSD, nearest, notified, persisted, persistent, personnel, proportionate, proportionately, proxy, ratio, receptor, retrospectively, SPA, tropism, valuable, vendor

Removed: enterococci, exceed, fifty, halting, permitting, Plant, submission

From filing 10-Q 2022 Q2

Financial reports

View all